# Immunology Core

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2022 · $262,277

## Abstract

Core E: Immunology
ABSTRACT
The mission of the Penn CFAR Immunology Core (Core E) is to support and promote innovative,
interdisciplinary, and translational research that enhances our understanding of the pathogenesis and
immunopathogenesis of HIV/AIDS, and that advances the development of novel vaccines and
immunological approaches to treatment and cure. Under the leadership of Director Dr. Jim Riley and new
Co-Director Dr. Eline (Nina) Luning Prak, the Core provides state-of-the-art immunological services, equipment,
reagents, and training to basic and clinical investigators, and has introduced an expanding set of emerging
platforms to both support and lead the research agenda. The services that Core E provides are grouped into
four broad areas:
1. Immunological assays using ACTG and/or IMPAACT approved assays for HIV/AIDS research; emerging
technologies such as single-cell analyses, ultrasensitive measurements, and B/T cell repertoire analysis;
consultation and assistance with experimental design and data analysis; specimen processing and storage; and
specialized, validated protocols to support Phase 1 clinical trials of immunotherapies targeting HIV.
2. Access to cutting-edge equipment including Luminex, 10X Genomic Chromium for single cell analytic
capacity, and Quanterix Simoa ultrasensitive digital ELISA in support of novel approaches, along with training in
use of these technologies.
3. Large volume highly purified human blood cell subsets from both uninfected and HIV-infected individuals,
providing extraordinary efficiency for CFAR investigators and economy of scale.
4. A small animal model of HIV-1 infection for in vivo studies of the HIV-1 latent reservoir, adoptive T cell and
other cutting-edge therapeutic approaches and HIV-1 pathogenesis, and which provides preclinical support for
novel cell-based and gene therapy interventions.
To amplify capacity and exploit the extraordinary immunology resources on the CFAR campus, Core E has
established strategic partnerships with other immunology-focused entities to leverage their expertise and
resources to support CFAR investigators. In the current reporting period, Core E supported 39 CFAR
investigators, over 70 NIH-funded applications, contributed to 150 publications, and generated nearly
$2M in chargebacks. This resulted in high-impact advances in HIV cure, reservoirs, innovative therapeutics
and other priority areas. Looking ahead, the Immunology Core will continue to support the breadth of CFAR
investigators, expand its already-deep collaborations with the Clinical and Virus & Reservoirs Cores, continue to
develop services to support the HIV Reservoirs & Tissue Immunology SWG, and play a key role in several large
clinical studies that will help lead the field in how to best engage the immune system to promote HIV remission
without antiretroviral therapy.

## Key facts

- **NIH application ID:** 10463867
- **Project number:** 5P30AI045008-24
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** James L. Riley
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $262,277
- **Award type:** 5
- **Project period:** 1999-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10463867

## Citation

> US National Institutes of Health, RePORTER application 10463867, Immunology Core (5P30AI045008-24). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10463867. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*